Kyverna Therapeutics (KYTX) Accumulated Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Accumulated Expenses data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 1.14% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 1.14% YoY) and the FY2025 annual result came in at $10.0 million, up 104.59% from the prior year.
• Accumulated Expenses fell to $3.1 million in Q1 2026, from $10.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.0 million in Q4 2025 to a low of $1.4 million in Q1 2024.
• A 4-year average of $4.4 million and a median of $3.8 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Accumulated Expenses surged 125.9% — and 2026, when it gained 1.14%.
• Tracing KYTX's Accumulated Expenses over 4 years: stood at $2.8 million in 2023, then jumped by 73.65% to $4.9 million in 2024, then soared by 104.59% to $10.0 million in 2025, then tumbled by 68.83% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $10.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.